Trends Towards Standardisation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Trends Towards Standardisation


Pharmaceutical Technology Europe
Volume 23, Issue 2

This is the first of a series of columns that I have agreed to write on single‑use manufacturing technologies and issues for BioPharm International (BPhI) and Pharmaceutical Technology Europe (PTE), which are sister publications. I want to start by acknowledging former BPhI Editor Laura Bush, who invited me to do this, to welcome Senior Editor Michelle Hoffman, and to thank Managing Editors Chitra Sethi (BPhI) and Fedra Pavlou (PTE), whom I look forward to working with. I also want to acknowledge Andrew Sinclair and Miriam Monge, who did a great job with this column in BPhI over the last several years and who have set a high bar in passing the baton.

I’ve written several editorials and articles for both BPhI and PTE in the past, and I am also a member of the Editorial Advisory Boards for both of these publications, but for those who are not familiar with me, I’ve been in the biopharmaceutical industry for over 31 years and have worked in filtration process development and validation with many pharmaceutical and biotech companies since before the biotech revolution. As an active member of the Parenteral Drug Association (PDA), the International Society for Pharmaceutical Engineering (ISPE), the American Society for Mechanical Engineering — BioProcess Equipment Committee (ASME-BPE) and, more recently, the Bio-Process Systems Alliance (BPSA), I’ve been a contributor or reviewer on numerous industry guides and standards, and have conducted trainings for regulatory agencies in the Western hemisphere, Europe and Asia. In my present role as Chairman of the Board and the Technology Committee of the BPSA, I have had the opportunity to interact with suppliers and users of single-use technologies worldwide and look forward to sharing that perspective here.


Jerold Martin
During the past 10 years or so, we've seen singleuse technologies explode from production-scale filter capsules, tubing and simple biocontainers to encompass sterile connectors, membrane chromatography adsorbers, bioreactors, mixers, and integrated platform systems with increasing levels of sensors and automated controls. Many articles have been published and singleuse conferences have become regular events, with topics evolving from fundamental technologies to user evaluations and on to process and facility integration.

The main issues today include: implementation, quality, security of supply, regulatory expectations, system design, integrity/installation testing, QbD, PAT, quality agreements, standardisation, disposal and environmental issues, economic justification, and many more. As this column progresses, let me know what singleuse issues and topics you would like to see further explored. This month, I will touch on some recent developments in standardisation and quality agreements, and provide an update on some of the latest BPSA initiatives in this area.

Standardisation of singleuse has become a frequent topic in articles, on chat boards and at conferences. Interest has been expressed for standardising materials for films and tubing, as well as the dimensions of sterile connectors, hose barb and sanitary flange fittings. When considering standardisation of singleuse components, it is important to bear in mind that while some aspects of singleuse can be standardised (e.g., approaches to sterilisation, characterisation of extractables, particle and endotoxin testing, tubing ID, hose barb and flange dimensions), it is unlikely that any materials or design features will become a commodity subject to standardisation because of the proprietary nature of many singleuse components. Other than ASMEBPE or ASTM International, none of the primary industry professional or trade associations (PDA, ISPE and BPSA) or regulatory bodies issue formal standards. Pharmaceutical standards bodies, such as the US or European Pharmopoiea or the International Organization for Standardization (ISO), tend to focus more on the final drug product and packaging. These can be extrapolated or adapted to singleuse equipment, but the industry organisations themselves primarily issue best practice recommendations and technical guides rather than formal or obligatory standards.

One of the key roles of the BPSA, in addition to producing its own best practice guides, is to provide stimulus to other organisations to also develop guides or standards that facilitate singleuse equipment implementation. For example, the BPSA recently submitted a letter to the ASME encouraging a review of the ASME-BPE standard for sanitary flange fittings with regard to using polymeric material instead of traditional metal alloys. The current ASMEBPE Standard for Sanitary Flanges was developed with stainless steel in mind, and specifies dimensions and tolerances that are costly to achieve in a variety of polymers. A modified standard addressing the properties of polymer-based flange connectors that maintains critical fitment requirements, while accommodating the unique properties of molded polymers, could reduce cost of ownership and ensure that all involved parts can interwork with both singleuse and stainless steel systems. For flange connector manufacturers, tooling and production costs could also be reduced if more liberal tolerances were allowed.

Many singleuse systems integrators now offer standardised singleuse assembly configurations for common functions, or subassemblies that can be customassembled aseptically with sterile connectors by the user. Such rationalisation can help reduce complexity and cost, but further standardisation of designs or materials among suppliers is both practically difficult and would be a barrier to further product developments. Singleuse technology may have moved out of its infancy, but standardisation to create commodities needs to be considered very carefully. Establishing standards for equivalency of designs or materials would stifle innovation and be counter to market demands for improved designs and materials.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here